$4.64 $0.12 (0.0%)

04:00 PM EDT on 06/24/19

Neon Therapeutics, Inc. (NASDAQ:NTGN)

CAPS Rating: No stars

Current Price $4.64 Mkt Cap $136.6M
Open $4.59 P/E Ratio 0.00
Prev. Close $4.64 Div. (Yield) $0.00 (0.0%)
Daily Range $4.45 - $4.68 Volume 21,747
52-Wk Range $4.20 - $7.49 Avg. Daily Vol. 3

Caps

How do you think NASDAQ:NTGN will perform against the market?

Add Stock to CAPS Watchlist

All Players

1 Outperform
2 Underperform
 

All-Star Players

0 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NTGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NTGN VS S&P 500 (SPY)

NASDAQ:NTGN Summary

Fools bullish on NASDAQ:NTGN are also bullish on:

Fools bearish on NASDAQ:NTGN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NTGN.

Recs

0
Member Avatar shanelofgren (31.55) Submitted: 7/9/2018 5:08:11 PM : Underperform Start Price: $13.24 NASDAQ:NTGN Score: +70.46

Bet against the neoantigen hypothesis (that all/most T cells reactive against a tumor are reacting against neoantigens and thus that vaccines will only be effective if they stimulate such T cells). I don't think neoantigen vaccines will be much more effective than TAA vaccines (and the TAA hypothesis is much more reasonable in TAA+ melanoma, and still it didn't work well there).

Also, vaccines have very low success rates in general. Not clear that they address the key issues (immune suppression / exhaustion in T cell inflamed tumors. Poor trafficking in non-T cell inflamed tumors).

And then on top of that, creating personalized vaccines from patient specific neoantigens seems very hard and expensive, unlikely to yield high revenues anytime soon.

That said, early exciting clinical PoC data could definitely make this jump, so I'm in for a long bumpy ride.

Leaderboard

Find the members with the highest scoring picks in NTGN.

Score Leader

WildShaman

WildShaman (93.97) Score: +71.59

The Score Leader is the player with the highest score across all their picks in NTGN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
WildShaman 93.97 7/9/2018 Underperform 5Y $13.40 -65.37% +6.22% +71.59 0 Comment
shanelofgren 31.55 7/10/2018 Underperform 5Y $13.24 -64.95% +5.51% +70.46 1 Comment
ssfinanchill 35.61 4/2/2019 Outperform 3M $6.58 -29.48% +2.69% -32.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NTGN.

Advertisement